ProAxsis’ ProteaseTag® technology will again be featured at the Winter meeting of the British Thoracic Society, which takes place between December 6^th-8^th at the Queen Elizabeth II Conference Centre, in London. Further details of the abstracts accepted for presentation by the conference review committee are detailed below:

NEATstik® – A Novel Point-of-Care Test for the Measurement of Active Neutrophil Elastase in Patients with Respiratory Disease (Poster no. 116).

Presenting author: Dr Kelly Moffitt (ProAxsis Limited)

Session – Infected lung: from bench to bedside

Thursday 7^th December

It is possible to detect active neutrophil elastase in exhaled breath condensate of patients with cystic fibrosis (Poster no. 249).

Presenting author: Dr Claire Edmondson (NHLI Imperial College and Royal Brompton Hospital, London)

Session – Clinical implications of cystic fibrosis

Friday 8^th December

Dr David Ribeiro, CEO of ProAxsis, said: “The BTS stated goal is to improve standards of care for people who have respiratory diseases, and the organisation currently has more than 3400 members. Having recently registered a European CE Mark for our rapid neutrophil elastase point-of-care test, NEATstik®, ProAxsis is delighted to be sharing the first data for this exciting new product at the BTS meeting.”

ProAxsis is part of the NetScientific group and is one of the group’s core portfolio companies. The company is also supported by QUBIS, the commercialisation arm of Queens University.

To find out how ProAxsis can support the measurement of active protease biomarkers of disease, or for any further queries, please contact info@proaxsis.com.